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Hepatitis B virus X protein (HBx) plays a crucial role in the development of hepatocellular carcinoma (HCC). However, the
signiﬁcance of circulating antibody to hepatitis B virus X antigen (anti-HBx) in sera remains unclear. In the present study, we
examined the titers of anti-HBx (IgG) in the sera from 173 patients with chronic hepatitis B (CHB), 106 liver cirrhosis (LC), and
61 HCC by enzyme-linked immunosorbent assay (ELISA), respectively. Our data showed that the positive rates of anti-HBx were
higher in sera of LC (40.6%) and HCC (34.4%) than those of CHB (10.4%), P<. 05. In all 40 patients with anti-HBx+ out of 340
patients, 39 (97.5%) were HBsAg/HBeAg/anti-HBc+ and 1 (2.5%) was anti-HBs+ (P<. 01), suggesting that anti-HBx in sera is a
marker of HBV replication rather than a protective antibody. Thus, our ﬁndings reveal that circulating anti-HBx in sera is one of
the markers of development of LC and HCC mediated by HBV.
Copyright © 2009 Hang Zhang et al. This is an open access article distributed under the Creative Commons Attribution License,
which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
1.Introduction
Infection of hepatitis B virus (HBV) always leads to liver cir-
rhosis (LC) and hepatocellular carcinoma (HCC) [1–3]. The
proportion of people infected with HBV in China is higher
than that in other countries. HBV is the prototype member
of the hepadnaviridae family and consists of a circular
partially double-stranded DNA molecule of 3.2kb in length
which contains four open reading frames (ORFs) that code
forsurfaceproteins(HBsAg),coreproteins(HBcAg/HBeAg),
the viral polymerase, and the transcriptional transactivator
Xp r o t e i n[ 1]. Previously, we found that the positive rate
of hepatitis B virus X antigen (HBxAg) was 76.5% in HCC
tissues by immunohistochemistry [4]. The integration of
HBV DNA into the host genome may be associated with
the development of HCC [5, 6]. The hepatitis B virus X
protein (HBx) is a 154 amino acid polypeptide, which has
a molecular weight of 17kDa. It has been reported that
HBx plays an important role in the development of HCC.
The HBx protein has been implicated in many functions
associated with liver diseases such as chronic hepatitis B
(CHB), LC, and HCC. The antibodies to HBxAg (anti-
HBx) may serve as a preneoplastic marker for HCC [7].
However, the studies of the correlation of HBxAg and anti-
HBx antibodies with the intensity of HBV replication or
the clinical status of HBV-infected patients are conﬂicting in
reports [8–10]. Hwang et al. reported that the positive rate
of anti-HBx in sera of HCC patients was 70%, while 5% of
serafromCHBpatientscontainedantibodieswithsigniﬁcant
binding to the HBx protein [9]. The detection of HBxAg
in patients’ sera or in liver tissues also has been reported
[4, 11–13]. Several researches have reported that HBx gene
w a sd e t e c t a b l ei nH C Ct i s s u e s[ 14, 15]. However, at present
few data show the relationships between HBxAg/anti-HBx in
sera and development of liver diseases with HBV infection,
such as CHB, LC, and HCC.
In our present study, we examined HBxAg and anti-HBx
(IgG) in a large amount of serum samples from patients2 Journal of Biomedicine and Biotechnology
suﬀering from CHB, LC, and HCC by enzyme-linked
immunosorbent assay (ELISA). HBx gene was detected by
PCR in the genome of HCC tissues as well. Our ﬁndings
showthattheanti-HBxinseraisamarkerofHBVreplication
rather than a protective antibody, particularly it is one of
markers of development of LC and HCC mediated by HBV.
2.MaterialsandMethods
2.1. Materials. Serum samples were taken from 173 patients
with CHB (116 males and 57 females aged 14–69 years,
with an average age of 38), 106 patients with LC (72
males and 34 females aged 23–81 years, with an average
age of 53), and 61 patients with HCC (48 males and 13
females aged 23–76 years, with an average age of 57). All
of the samples were obtained from Tianjin Third Central
Hospital, Tianjin and Aﬃliated Hospital, Chengde Medical
College, Chengde, China, respectively. Forty ﬁve cases of
HCC tissues were taken from Tianjin First Central Hospital,
Tianjin, China (totally, 42 males and 3 females aged 21–
70 years, with an average age of 51.9). According to the
hospital records, all patients underwent total or subtotal
hepatectomy followed by pathologic diagnosis showed the
examination of HBV markers, such as HBsAg, antibody
to HBsAg (anti-HBs), HBeAg, antibody to HBeAg (anti-
HBe), and antibody to HBcAg (anti-HBc). Normal sera
of 213 individuals were taken from healthy examination
(Tianjin, China). We obtained the ethics approve for using
the materials of sera and HCC tissues from Hospital’s Ethics
Committees.
2.2. Methods
2.2.1. Plasmid Constructions and Protein Puriﬁcation. Full-
length of HBx gene PCR product was obtained by PCR using
pCMV-X plasmid (kindly provided by Dr. A. Graessmann)
as template. According to the known HBx sequence (Gen-
Bank accession number AB104894.1), the primer sequences
were forward, 5 -CAGAATTCATGGCTGCTAGGCTGTGC-
3 , including the restriction site of EcoRI and ATG; reverse,
5 -ATCTCGAGAGAAGTCGTCGTCGTCC-3 , including the
restrictionsiteofXhoIandTAA.Theampliﬁcationcondition
consisted of 30 cycles at 94
◦C for 30seconds, 60
◦Cf o r
30seconds, and 72
◦C for 45seconds. The resulting PCR
product was inserted into the pMD18-T vector (Takara,
China) to yield pMD18-T-HBx. This construct was digested
withEcoRI and XhoI, and the HBx gene fragment was ligated
into the pET-30a vector containing His-Tag (Novagen,
USA) to generate pET-30a-HBx, followed by conﬁrmation
using sequence. His-HBx fusion proteins were expressed in
Escherichia coli BL21 (DE3) by induction with 0.5mmol/L
isopropyl-β-D-thiogalactopyranoside (IPTG) at 37
◦Cf o r
4hours. Cells were harvested and sonicated in Phosphate
Buﬀered Saline (PBS; 50mmol/L NaH2PO4, 30mmol/L
NaCl, 20mmol/L Imidazole, pH 8.0). After centrifuga-
tion the sedimentation was collected. For puriﬁcation, the
extracts were denatured by buﬀer B (100mmol/L NaH2PO4,
10mmol/L Tris-HCl, 8mol/L Urea, 20mmol/L Imidazole,
75mg/mL Phenylmethanesulfonyl ﬂuoride, pH 8.0), and
then incubated with Ni-NTA agarose (QIAGEN, USA) at
room temperature for 1 hour. The beads were precipitated
and washed according to the instruction. The puriﬁed His-
HBx fusion protein was detected by sodium dodecyl sulfate
(SDS)-polyacrylamide gel electrophoresis (PAGE). Thus, the
eluted proteins were divided.
2.2.2. Generation of Rabbit Anti-HBx Antibodies. His-HBx
fusion protein was used to raise rabbit anti-HBx antibodies.
Brieﬂy, approximately 1mg of His-HBx fusion protein was
mixed with complete Freund’s adjuvant (Sigma, USA) and
was subcutaneously injected into three rabbits, respectively.
Booster injections consisting of 500μg of proteins with
incompleteFreund’sadjuvant(Sigma)weregiventhreetimes
at 7-day intervals. Sera were taken by bleeding from the ear
vein each time before injection. After 6weeks, the rabbits
were killed and sera were taken by bleeding from the carotid.
The antibodies of rabbit against HBx were puriﬁed from the
immune sera by aﬃnity puriﬁcation. The characteristics of
rabbit anti-HBx antibodies were identiﬁed by Western blot
analysis as the above protocol in a model of H7402-X cells
[4], in which HBx was expressed.
2.2.3. Identiﬁcation of Rabbit Anti-HBx Antibodies. To iden-
tify the generated rabbit anti-HBx antibodies, we examined
HBx protein in H7402-X cells stably transfected with HBx
gene [4] by Western blot analysis, using generated rabbit
anti-HBx polyclonal antibodies and mouse anti-HBx mono-
clonalantibody,respectively.H7402-Pcellsstablytransfected
with empty pcDNA3 vector [4] and H7402 cells were used
as controls. The cells were lysed in lysis buﬀer (62.5mmol/L
Tris-HCl, pH 6.8, 2% SDS, 5%β-mercaptoethanol, 10%
glycerol). Equal amounts of protein (30μg) were separated
by 15% SDS-PAGE and transferred onto a nitrocellulose
membrane for 1hour. The membrane was blocked in
blocking buﬀer (PBS, 5% skim milk, 0.1% Tween 20) at
room temperature for 2hours, and then incubated with the
appropriate primary antibody (diluted in blocking buﬀer).
The primary antibodies were mouse anti-HBx (1: 5000
dilution,Chemicon,USA),ourgeneratedrabbitanti-HBx(1:
1000 dilution) and β-actin (1: 5000 dilution, Sigma, USA).
The membranes were then washed three times in PBS with
0.1% Tween 20 and incubated for 1hour in the secondary
antibody (peroxidase-conjugated antirabbit or antimouse
IgG). The membranes were then washed three times, and the
bands were visualized by ECL (Amersham, USA).
2.2.4. Examination of HBxag and Circulating Anti-HBx (IgG)
in Sera. HBxAg and circulating anti-HBx (IgG) in all sera
from 340 patients with CHB, LC and HCC as well as
213 healthy individuals were detected by enzyme-linked
immunosorbent assay (ELISA). We examined the circlating
anti-HBx (IgG) in sera by an indirect ELISA method [12].
The following examination was used as positive control.
Puriﬁed 100μL of His-HBx fusion protein was immobilized
on the bottoms of wells (10μg / w e l l )o fa9 6 - w e l lp l a t ei n
triplicate overnight at 4
◦C. After treatment with 3% bovineJournal of Biomedicine and Biotechnology 3
serum albumin (BSA) at 37
◦C for 1hour and washed,
then reacted with 50μL puriﬁed antibodies of rabbit anti-
HBx at 37
◦C for 1hour and washed, ﬁnally the antigen-
antibody complex was detected by a peroxidase-conjugated
goat antihuman IgG (1: 2000 dilution) and the oxidation of
ortho-phenyldiamine.Thedegreeofoxidationwasmeasured
at 490nm. Meanwhile, we examined the circlating anti-HBx
(IgG) in sera from patients, such as CHB, LC and HCC as
above protocol.
Then, we examined the HBxAg in sera from patients,
such as CHB, LC, and HCC by an indirect ELISA method
[12]. Mouse anti-HBx monoclonal antibody (Chemicon,
USA) was immobilized on the bottoms of wells of a 96-
well plate in triplicate (10μg/well) at 4
◦C overnight. After
treatment with 3% BSA, washed with PBS, and reacted with
the patients’ sera at 37
◦C for 1hour, washed with PBS, then
reactedwithpuriﬁedrabbitanti-HBxpolyclonalantibody(1:
250 dilution) at 37
◦C for 1hour, washed with PBS, ﬁnally
the antigen-antibody complex was detected by a peroxidase-
conjugated goat antirabbit IgG (1: 2,000 dilution) and the
oxidation of ortho-phenyldiamine. The degree of oxidation
was measured at 490nm.
2.2.5. Examination of HBx Gene in the Genome of HCC
Tissues. The DNA from HCC tissues was extracted using
a standard proteinase K digestion and phenol/chloroform
method [16]. The resultant DNA was PCR-ampliﬁed in a
ﬁnal volume of 50μL containing 1μL DNA as template and
deoxyribonucleoside triphosphates (10mmol/L each), 2.5U
of Ex Taq (Takara, China), and 0.2μmol/L of each primer.
The HBx gene speciﬁc primers were designed according
to the sequence of HBx gene (Genbank: AB 104894.1,
National Institutes of Health, Bethesda, Md). The primer
sequences were sence, 5 -GCGCACCTCTCTTTACGC-3 ,
and antisence, 5  -CGTTGGCCGATTCATTAATG-3 .T h e
PCR program is 94
◦C for 20 minutes, followed by 10cycles
at 94
◦C for 30seconds, 65–55
◦C for 45seconds, 72
◦Cf o r
1minute, and drop the annealing temperature for 1
◦Ci n
each cycle, followed by 20 cycles at 94
◦C for 30 seconds,
55
◦C for 45seconds, 72
◦C for 2 minutes and elongate at
72
◦C for 10minutes. The PCR products were separated
by electrophoresis on a 1.5% agarose gel and visualized
with the use of ethidium bromide staining. The prospected
PCR product is 350bp. The template was not added in the
negative control in the PCR system. The plasmid of pCMV-
X cloned HBx gene [4] was used as positive control in the
PCR system.
2.2.6. Statistical Analysis. Multiple comparisons for statis-
tically signiﬁcant diﬀerences in HBxAg or anti-HBx titers,
measured in optical density (OD), were performed in the
sera among patients with CHB, LC, HCC, and healthy
individuals by a Tukey test [12]. The signiﬁcant diﬀerence
between the positive rates of HBsAg/HBeAg/anti-HBc and
anti-HBs in the group of HBxAg-positive patients was
performed by X2 test. The result are considered as signiﬁcant
when the statistical test is ≤ 0.05.
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Figure 1: Identiﬁcation of rabbit anti-HBx polyclonal antibody.
HBx in H7402-X, H7402-P, and H7402 cells was examined by
Western blot analysis, using generated rabbit anti-HBx polyclonal
antibody and mouse anti-HBx monoclonal antibody, respectively.
The results showed that the generated rabbit anti-HBx polyclonal
antibody was eﬀectively able to recognize HBx in H7402-X cells as
mouse anti-HBx monoclonal antibody did.
∗∗
∗∗
CHB LC HCC
0
0.1
0.2
0.3
0.4
0.5
0.6
0.7
0.8
O
D
(
4
9
0
n
m
)
Figure 2: ELISA showed the quantities of anti-HBx (IgG) in sera
from clinical CHB patients, LC patients, HCC patients. The value
in each group was mean OD (
∗∗P <. 01, versus CHB, Tukey test).
3. Results
3.1. Identiﬁcation of Rabbit Anti-HBx Antibodies. The HBx
gene was successfully constructed into the pET-30a vector,
termed pET-30a-HBx, in which the sequence was conﬁrmed
by sequencing. To examine HBxAg and circulating anti-HBx
in sera, we generated rabbit anti-HBx antibodies speciﬁc to
HBx. The characteristics of the anti-HBx antibodies were
conﬁrmed by Western blot analysis. The data showed that
the HBx could be recognized either by monoclonal anti-HBx
antibody or generated polyclonal rabbit anti-HBx antibodies
inH7402-XcellsstablytransfectedwithHBxgene(Figure1),4 Journal of Biomedicine and Biotechnology
HBx gene
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Figure 3: Examination of HBx gene in HCC tissues by PCR. The
results revealed that the HBx gene-positive rate was 77.8% (35/45)
in HCC tissues. The PCR products of no. 1–10 HCC patients were
shown. (−) means negative control without adding template in
the PCR system. (+) means positive control using the plasmid of
pCMV-X cloned HBx gene as template in the PCR system.
suggesting that the speciﬁcity of the polyclonal rabbit anti-
HBx antibodies is well.
3.2. Titers of Circulating Anti-HBx Are Higher in Sera of
LC and/or HCC Than CHB. After the generation of rabbit
anti-HBx, the quantities of HBxAg and anti-HBx (IgG) in
sera were demonstrated by ELISA (Figure 2). The results
showed that the positive rates of HBxAg/anti-HBx (IgG)
were 8.7%/10.4% in 173 CHB sera, 17.9%/40.6% in 106
LC sera (P<. 01, versus CHB anti-HBx+, Tukey test), and
9.8%/34.4% in 61 HCC sera (P<. 01, versus CHB anti-
HBx+, Tukey test), respectively, (Table 1) suggesting that
the titers of anti-HBx (IgG) in sera of LC and/or HCC
patients were higher than those of CHB patients. Table 2
showed that 21 out of 23 HBxAg-positive patients were
HBsAg/HBeAg/anti-HBc-positive (91.3%), but only 2 out
of 23 ones were anti-HBs positive (8.7%) (P<. 01, X2
test). In all 40 patients with anti-HBx (IgG) positive, 39
were HBsAg/HBeAg/anti-HBc positive (97.5%) and 1 was
anti-HBs positive (2.5%) (P<. 01, X2 test), suggesting
that the circulating anti-HBx (IgG) in sera is a marker
of HBV replication rather than a protective antibody, and
the circulating anti-HBx in sera is one of the markers of
development of LC and HCC mediated by HBV. In control,
both HBxAg and anti-HBx (IgG) were totally negative in all
213seraofhealthyindividuals.Figure2showedthatthetiters
of anti-HBx (IgG) were higher in sera of 106 LC patients,
61 HCC patients than those of 173 CHB patients by ELISA
(P<. 01, Tukey test). In sex, 65.0% (26/40) HBxAg-positive
patients were males (8/15 CHB, 13/19 LC, 5/6 HCC), while
67.0% (55/82) anti-HBx-positive (IgG) patients were males
(14/18 CHB, 23/43 LC, 18/21 HCC).
3.3. Persistence of HBx Gene in HCC Tissues. We examined
the HBx gene in the 45 HCC tissues by PCR. HBx gene
was detectable in 35 cases (77.8%). The PCR products were
shown in Figure 3, suggesting that HBx gene was persistent
in HCC tissues, which may integrate into the genome of liver
cells or work as dissociative virus in the cells.
4. Discussion
During the past few decades, the HBV markers, such as
HBsAg, anti-HBs, HBeAg, anti-HBe, and anti-HBc, in sera
of patients infected with HBV were routinely examined for
general diagnosis of HBV infection [17, 18]. Up to now,
the clinical signiﬁcance of HBxAg and anti-HBx in sera
has not been thoroughly clariﬁed. In our present study,
we used the full-length HBx protein as antigen to generate
rabbit anti-HBx antibodies. Thus, it is necessary to use
puriﬁed full-length HBx protein as an antigen to test the
accurate titers of anti-HBx in sera from various sources
[9, 19]. In our experiment, the puriﬁed recombinant His-
HBx protein was used as an antigen to immune rabbits,
and got a good immune response. Using mouse anti-HBx
monoclonal antibody as positive control, we found that
the rabbit anti-HBx antibodies have good speciﬁcity and
sensitivity by Western blot analysis. Based on the established
ELISA method, we examined HBxAg and titers of anti-HBx
(IgG) in sera of many patients infected with HBV. All of
the carriers were carefully selected from diﬀerent relevant
stages in the natural history of chronic HBV infection with
examination of HBV serum markers. However, in diﬀerent
reports the positive rates of HBxAg and anti-HBx in the sera
ofthepatientswerevariedwiththeusedHBxproteinorHBx
oligopeptides [5].
Currently, the clinical serum markers of HBV infection
include HBsAg/anti-HBs, HBeAg/anti-HBe, anti-HBc [20,
21], HBV DNA, and so forth [22, 23]. Usually, the detection
of above ﬁve serum markers and HBc-IgM was performed by
ELISA method. However, at present the clinical serological
detection of HBxAg and anti-HBx is not launched for
hepatitis, cirrhosis, and liver cancer. Therefore, the clinical
signiﬁcance of serum HBxAg and anti-HBx remains unclear.
In our present study, for HBxAg detection we found that
the HBxAg-positive rate was only 9.8% (6/61) in sera of
HCC patients. While for anti-HBx detection, one report
demonstrated that the anti-HBx-positive rate was 70% in
sera of 20 HCC patients [9]. In contrast, our data showed
that the anti-HBx (IgG)-positive rates were 40.6% in sera of
LC patients and 34.4% in sera of HCC patients (Table 1),
respectively. Moreover, the quantities of anti-HBx (IgG) in
theseraofLCorHCCpatientswerehigherthanthoseinsera
of CHB patients as well (Figure 2) , suggesting that the titers
of anti-HBx in sera were closely related to the development
of LC or/and HCC.
As we know, the anti-HBs in sera is a protective antibody
after HBV infection or vaccination for hepatitis B vaccine.
The HBsAg/HBeAg/anti-HBc-positive in sera means the
replication of the viruses, and the patients are infectious.
However, our data (Table 2) suggest that the anti-HBx in
sera is not a protective antibody. The anti-HBx-positive
patients are infectious. In this study, we found that 65.0%
HBxAg-positive patients and 67.0% anti-HBx-positive (IgG)
patients were males, suggesting that the male patients may
be the risk population for the development of HCC. As we
know, the integration of HBV DNA in the host genome
was a frequent event in HCC tissues [24, 25]. It has been
reported that the detection rate of HBV DNA integration
was increased in parallel with the progress of liver histology
towards the neoplastic transformation [26]. However, it has
been reported that the HBV DNA integration-positive rate
is low in chronic hepatitis tissues, but high in liver tumorJournal of Biomedicine and Biotechnology 5
Table 1: Examination of HBV serum markers in CHB, LC, and HCC patients.
Diseases No. HBsAg (%) Anti-HBs (%) HBeAg (%) Anti-HBe (%) Anti-HBc (%) HBxAg (%) Anti-HBx (IgG) (%)
CHB 173 172 (99.4) 5 (2.9) 71 (41.0) 120 (69.3) 173 (100) 15 (8.7) 18 (10.4 )
LC 106 86 (81.1) 9 (8.5) 48 (45.3) 82 (77.4) 105 (99.1) 19 (17.9) 43 (40.6)
∗
HCC 61 46 (75.4) 5 (8.2) 17 (27.9) 45 (73.8) 56 (91.8) 6 (9.8) 21 (34.4)
∗
CHB chronic hepatitis B; LC liver cirrhosis; HCC hepatocellular carcinoma. X2 test, ∗P<. 01 (versus CHB).
Table 2: Clinical signiﬁcance of HBxAg and anti-HBx in sera
Clinical signiﬁcance HBxAg+ (%) anti-HBx+ (IgG) (%)
HBsAg/HBeAg/anti-HBc+ 21 (91.3)
∗ 39 (97.5)
∗
Anti-HBs+ 2 (8.7) 1 (2.5)
Total 23 (100) 40 (100)
X2 test ∗P<. 01 (versus anti-HBs+).
tissues (66.7%) [27]. Another study which measured the
intrahepatic HBV DNA and covalently closed circular DNA
(cccDNA) levels in tumor and nontumor tissues in HCC
patients has reported that the levels of HBV replication in
the tumor tissues appeared to be lower compared to the non-
tumor tissues. But the tumor tissues had signiﬁcantly higher
proportionofintrahepaticHBVDNAintheformofcccDNA
than the non-tumor tissues [28]. In our present study, we
found that the HBx gene-positive rate was 77.8% in HCC
tissues by PCR, suggesting that HBx gene was persistent in
HCC tissues, which may integrate into the genome of liver
cells or as dissociative virus in the cells.
Taken together, our ﬁndings show that anti-HBx in sera
is a marker of HBV replication rather than a protective
antibody. The circulating anti-HBx in sera is one of the
markers of development of LC and HCC mediated by HBV.
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